Related Experiment Video
Updated: Aug 29, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats
R Miatello1, N Risler, C Castro
1Dept. of Pathology, School of Medicine, National University of Cuyo, Av. Libertador 80, Centro Universitario 5500, Mendoza, Argentina. rmiatell@fcm.uncu.edu.ar
Abstract:
The cluster of risk factors including hyperinsulinemia, insulin resistance, hypertriglyceridemia and hypertension has been called syndrome X. Several evidences link the insulin resistance syndrome with endothelial dysfunction. Since the participation of the renin-angiotensin system (RAS) in this pathology is still unclear, the present study examined the effect of chronic administration of an angiotensin AT1 receptor antagonist, losartan (L), on endothelial nitric oxide synthase (eNOS) activity in aortic endothelium and cardiac tissue, and on the proliferation of primary cultured aortic smooth muscle cells (SMC), obtained from fructose-fed rats (FFR), an experimental model of syndrome X Male Wistar rats were used: Control, FFR and FFR+L (n = 8 in each group). After 8 weeks, tissue samples were obtained and 10% fetal calf serum (FCS) proliferative effect was examined in SMC by 3H-thymidine incorporation and cell counting. The eNOS activity was estimated in aortic endothelial lining and cardiac homogenates by conversion of 3H-arginine into 3H-citrulline. FFR aortic SMC showed a significantly increased 10% FCS-induced 3H-thymidine incorporation and cell number compared to controls. FFR aortic and cardiac eNOS activities were significantly decreased. Chronic treatment with L decreased systolic blood pressure,reverted cardiac hypertrophy, abolished the increased SMC proliferation and restoredeNOS activity. These data confirm that changes in SMC proliferation and endothelial dysfunction at different levels of the cardiovascular system are involved in syndrome "X", and that AT1 receptor blocking can revert those changes, suggesting an important role of the RAS, possibly mediated by AT2 receptors and kinins, in the physiopathological mechanisms of this model.
Insights
Losartan treatment improved endothelial dysfunction and smooth muscle cell proliferation in rats with Syndrome X. This suggests the renin-angiotensin system plays a key role in this condition.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Syndrome X, characterized by hyperinsulinemia, insulin resistance, hypertriglyceridemia, and hypertension, is linked to endothelial dysfunction.
- The role of the renin-angiotensin system (RAS) in Syndrome X remains unclear.
Purpose of the Study:
- To investigate the effect of losartan, an angiotensin AT1 receptor antagonist, on endothelial nitric oxide synthase (eNOS) activity and smooth muscle cell (SMC) proliferation in a rat model of Syndrome X.
- To elucidate the involvement of the RAS in the pathophysiology of Syndrome X.
Main Methods:
- Fructose-fed rats (FFR) were used as a model for Syndrome X.
- Rats received chronic losartan (L) administration.
- eNOS activity was measured in aortic endothelium and cardiac tissue.
- SMC proliferation was assessed using 3H-thymidine incorporation and cell counting.
Main Results:
- FFR exhibited increased SMC proliferation and decreased aortic and cardiac eNOS activity compared to controls.
- Losartan treatment reduced systolic blood pressure and cardiac hypertrophy.
- Losartan administration restored eNOS activity and abolished increased SMC proliferation.
Conclusions:
- Endothelial dysfunction and altered SMC proliferation are key components of Syndrome X.
- AT1 receptor blockade with losartan effectively reverses these pathological changes.
- The RAS plays a significant role in Syndrome X, potentially involving AT2 receptors and kinins.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers

